You are currently viewing the summary.
View Full TextLog in to view the full text
AAAS login provides access to Science for AAAS members, and access to other journals in the Science family to users who have purchased individual subscriptions.
More options
Download and print this article for your personal scholarly, research, and educational use.
Buy a single issue of Science for just $15 USD.
Summary
Culminating a 33-year odyssey, scientists this week reported a milestone in type 1 diabetes: evidence that it can be held off. At the American Diabetes Association meeting in San Francisco, California, and in The New England Journal of Medicine, researchers reported that 2 weeks of an experimental drug delayed disease by an average of about 2 years in young people at very high risk. More than 1 million people in the United States have type 1 diabetes, which requires constant blood sugar monitoring and can lead to complications including heart disease and kidney failure. Years before diagnosis, the sentries of the immune system, T cells, begin to attack β cells in the pancreas. But those insulin-secreting cells are still largely intact, offering a window for intervention.
